1. 1-12 of 12
    1. Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease

      Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease

      Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market leading opto map® ultra-widefield retinal imaging devices to diagnose Alzheimer’s Disease in patients. Through this alliance, Optos and Amydis will collaborate on the clinical development of Amydis’ test for the detection of Alzheimer’s disease. The partnership will combine Optos’ market leadership with its proprietary ultra-widefield technology and ...

      Read Full Article
    2. Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Leipzig Interventional Course 2018

      Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Leipzig Interventional Course 2018

      Avinger, Inc. (NASDAQ: AVGR ), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next generation Pantheris® Lumivascular atherectomy system was featured in a live case transmission at Leipzig Interventional Course (LINC) 2018 held from January 30th through February 2nd at the Trade Fair Leipzig, in Leipzig, Germany. LINC is a leading global forum for new methods in the field of vascular medicine that brings together medical professionals from around the world who perform endovascular interventions. Yesterday Drs. Arne Schwindt and Stefan Stahlhoff, vascular surgeons from St. Franziskus Hospital in Münster, Germany, used the next ...

      Read Full Article
    3. Avinger’s Pantheris Named a 2017 Gold Edison Award Winner

      Avinger’s Pantheris Named a 2017 Gold Edison Award Winner

      Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease (PAD), was honored at the 2017 Edison Awards™ in the Medical/Dental Surgical Tool category with gold for Pantheris, the first-ever image-guided atherectomy device for the treatment of PAD. Avinger was nominated among hundreds of the world’s most recognized companies to acknowledge dedication and commitment of innovation to create a positive impact in the world. The ballot of nominees for the Edison Awards was judged by a panel of more than 3,000 leading business executives including past award winners, academics and leaders in the fields of ...

      Read Full Article
    4. Avinger Successfully Completes Vision Ide Trial for Pantheris(TM)

      Avinger Successfully Completes Vision Ide Trial for Pantheris(TM)

      Avinger, Inc., (NASDAQ: AVGR ) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that its Pantheris™ system has achieved all safety and efficacy endpoints in six-month follow-up data for its VISION IDE clinical trial. VISION was designed to evaluate the safety and effectiveness of Pantheris to perform directional atherectomy while for the first time ever allowing physicians to use real-time intravascular imaging to aid in the removal of plaque from diseased lower extremity arteries. VISION results from the 130 patients treated ...

      Read Full Article
    5. Avinger Announces Interim Six-Month VISION Trial Results at TCT 2015

      Avinger Announces Interim Six-Month VISION Trial Results at TCT 2015

      Avinger, Inc., ( AVGR ) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced interim six-month results for its VISION clinical trial. VISION is designed to evaluate the safety and effectiveness of the Pantheris(TM) system to perform directional atherectomy while for the first time ever allowing physicians to use real-time intravascular imaging to aid in the removal of plaque from diseased lower extremity arteries. VISION results were presented by Arne Schwindt, M.D. of St. Franziskus Hospital in Muenster, Germany, at the ...

      Read Full Article
    6. Lantis Laser Signs Letter of Intent to Merge With Perio-Imaging Inc.

      Lantis Laser Signs Letter of Intent to Merge With Perio-Imaging Inc.
      Lantis Laser Inc. (OTCBB:LLSR) (http://www.lantislaser.com), announced today that it has signed a Letter of Intent to merge with Perio-Imaging Inc., a private New York based company. The merger would be an all stock transaction and closing, among other conditions, would be subject to raising the required funding to complete the proposed merged company's product development program. The name of the new merged company will be announced upon closing.
      Read Full Article
    7. Michelson Diagnostics VivoSight OCT Scanner Receives FDA 510(k) Clearance

      Michelson Diagnostics VivoSight OCT Scanner Receives FDA 510(k) Clearance
      ORPINGTON, United Kingdom, Jan. 12, 2010 (GLOBE NEWSWIRE) -- Michelson Diagnostics Ltd, the London, UK based developer and manufacturer of Optical Coherence Tomography (OCT) products, announced today that the US Food & Drug Administration (FDA) has awarded it 510(k) clearance for its VivoSight(TM) OCT scanning product. For clinical use, FDA 510(k) K093520 applies: "VivoSight(TM) is a Multi-Beam Optical Coherence Tomography (OCT) system indicated for use in the two-dimensional, cross-sectional, real-time imaging of external tissues of the human body." VivoSight(TM) is the first Fourier-Domain OCT scanner to receive FDA 510(k) clearance, outside of the field of ophthalmology ...
      Read Full Article
    8. Michelson Diagnostics Receives New Funding to Accelerate Growth

      Michelson Diagnostics Receives New Funding to Accelerate Growth
      ORPINGTON, United Kingdom, Jan. 5, 2010 (GLOBE NEWSWIRE) -- Michelson Diagnostics Ltd, the London, UK based developer and manufacturer of Optical Coherence Tomography (OCT) products, has raised GBP664,000 ($1.1M) to fund the next stage of its growth. The new funding will enable Michelson to enlarge its sales force, perform larger, more comprehensive trials on multiple applications, and to prepare for volume clinical sales. Investors in the funding round included a syndicate of business angels drawn from London Business Angels and Oxford Investment Opportunity Networks, and from existing shareholders including Catapult Venture Managers Ltd and London Seed Capital Ltd. Michelson ...
      Read Full Article
    9. First Ever Report of Cellvizio(r) Use in Cystoscopy: New Data On World's Smallest Microscope Presented At American Urology Association (AUA) Annual Meeting

      PARIS, April 27, 2009 (GLOBE NEWSWIRE) -- New data show that real-time, in vivo imaging with Cellvizio(r), the world's smallest microscope, can be used in the urology field and may help urologists to differentiate low and high-grade bladder tumors from normal bladder tissue, according to data presented today at the American Urological Association's (AUA) Annual meeting being held in Chicago from April 25th to 30th. Cellvizio probe-based confocal laser endomicroscopy (pCLE) provides live images of internal human tissues at the cellular level during examination procedures enabling faster clinical decision making.
      Read Full Article
    10. Lantis Files 15(c) 2-11 With Finra to Obtain Listing On OTC Bulletin Board

      DENVILLE, N.J., April 1, 2009 (GLOBE NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), announced today that it has filed a 15(c) 2-11 with FINRA to obtain a quotation on the OTC Bulletin Board. Stan Baron, President & CEO, pointed out that being a fully reporting company will provide the transparency and credibility that investors require in today's economic environment. Lantis filed an S-1 with the SEC which was deemed effective on February 17, 2009.
      Read Full Article
    11. Lantis Laser CEO to Appear On AOL Finance Small Cap Show Produced by Agoracom

      DENVILLE, N.J., March 11, 2009 (GLOBE NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), announced today that its President & CEO, Mr. Stan Baron, can be heard all this week on the AOL Small Cap Show produced by AGORACOM Investor Relations.
      Read Full Article
    12. Lantis Announces President's Investor Update On Strategic Achievements

      Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), announced today that Stan Baron, President & CEO, released an official Update Letter to shareholders. Lantis is developing ground breaking light-based diagnostic imaging technology for application in dentistry.
      Read Full Article
    1-12 of 12
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks